Results of Operations and Financial Condition

Filing Summary

Registrant: Galecto, Inc. The request metadata identifies Damora Therapeutics, Inc., but the filing names Galecto, Inc. as the registrant.

Form 8-K date: January 6, 2023, covering information available as of December 31, 2022.

Financial Position and Key Metrics

  • Cash, cash equivalents and investments totaled approximately $66 million as of December 31, 2022.
  • The filing does not provide revenue, net income or loss, operating cash flow, margins, debt, liquidity runway, or other detailed financial metrics.

Material Changes and Disclosures

  • The filing reports the year-end cash, cash equivalents and investments balance; no comparable prior-period balance or change is provided.
  • Galecto furnished an updated corporate presentation dated January 2023 as Exhibit 99.1 for use in meetings with analysts, investors and others beginning January 6, 2023.
  • The presentation and related information were furnished under Regulation FD and are not deemed filed under Section 18 of the Exchange Act, except as expressly incorporated by reference.

Guidance, Outlook, Risks and Unusual Items

The filing does not provide financial guidance, operating outlook, risk updates, contingencies, or unusual items. The content of the referenced corporate presentation is not included in the supplied filing text, so related commentary cannot be evaluated.

Investor Verification Points

  • Verify the registrant identity and ticker: Galecto, Inc., Nasdaq Global Select Market, ticker GLTO.
  • Review Exhibit 99.1 for pipeline, clinical, corporate, financial and liquidity commentary not included in the filing text.
  • Confirm the approximately $66 million balance against the company’s subsequent periodic financial statements and assess expected cash utilization and financing needs.
  • Verify whether any material developments occurred after December 31, 2022, including clinical, regulatory, financing or strategic events.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.